Michael W. Sill

9.9k citations

110 papers · 6.2k indexed · 4 hit papers · h-index 36

Impact in

Reproductive Medicine top 0.1%
- Ovarian cancer diagnosis and treatment
Obstetrics and Gynecology top 0.1%
- Endometrial and Cervical Cancer Treatments

Papers in

Reproductive Medicine 70
- Ovarian cancer diagnosis and treatment 69
- Endometriosis Research and Treatment 8
Obstetrics and Gynecology 53
- Endometrial and Cervical Cancer Treatments 47

Co-authors: Bradley J. Monk Robert A. Burger Lois M. Ramondetta Benjamin E. Greer D. Scott McMeekin Krishnansu S. Tewari Joel I. Sorosky Kathleen M. Darcy
Journals: Gynecologic Oncology (66 papers)Journal of Clinical Oncology (21 papers)International Journal of Gynecological Cancer (4 papers)Journal of Midwifery & Women s Health (3 papers)Clinical Cancer Research (2 papers)
Partner nations: United States Spain Palestinian Territory

In The Last Decade

Michael W. Sill

108 papers receiving 6.1k citations

Hit Papers

align trajectories log scale

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study 2020 · 224 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Journal of Clinical Oncology
2014 New England Journal of Medicine
2009 Journal of Clinical Oncology
2007 Journal of Clinical Oncology

Peers

Countries citing papers authored by Michael W. Sill

Since Specialization

Citations

This map shows the geographic impact of Michael W. Sill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Sill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Sill more than expected).

Fields of papers citing papers by Michael W. Sill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael W. Sill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Sill. The network helps show where Michael W. Sill may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael W. Sill, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael W. Sill Line = papers co-authored together Michael W. Sill links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study Gynecologic Oncology ·Victoria Bae‐Jump, Michael W. Sill, Paola A. Gehrig, Jason D. Merker, David L. Corcoran, Adam D. Pfefferle, Michele C. Hayward, Joan L. Walker, Andrea R. Hagemann, Steven Waggoner, Roisin E. O’Cearbhaill, Megan McDonald, Mitchell I. Edelson, Paul DiSilvestro, Amy McNally, Aimee C. Fleury, Ramey D. Littell, Frederick R. Ueland, Heather A. Lankes, Carol Aghajanian	2025	1
2	Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014) Gynecologic Oncology ·Alison M. Schram, Ramez N. Eskander, Michael W. Sill, Andrea R. Hagemann, Steven Waggoner, Joshua Z. Press, Sharad Ghamande, Oliver Zivanovic, Justin Bottsford-Miller, Carol Aghajanian	2024	1
3	PO005LBA/#1579 A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009) Roisin E. O’Cearbhaill, Michael W. Sill, Hoa Duong, Steven Waggoner, Rachel N. Grisham, Floor Backes, Robert S. Mannel, János L. Tanyi, Matthew A. Powell, Cara Mathews, Sharad Ghamande, Leah McNally, Alexander Olawaiye, David Bender, Linda Duska, Heather A. Lankes, Dmitriy Zamarin, Russell J. Schilder, Michael A. Bookman, Carol Aghajanian	2023	0
4	Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study Gynecologic Oncology ·Krishnansu S. Tewari, Michael W. Sill, Michael J. Birrer, Richard T. Penson, Helen Huang, David H. Moore, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão, Helen E. Michael, Bradley J. Monk	2023	16
5	Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study Journal of Clinical Oncology ·Dmitriy Zamarin, Robert A. Burger, Michael W. Sill, Daniel J. Powell, Heather A. Lankes, Michael D. Feldman, Oliver Zivanovic, Camille C. Gunderson, Emily Ko, Cara Mathews, Sudarshan Sharma, Andrea R. Hagemann, Samir N. Khleif, Carol Aghajanian Hit paper breakdown →	2020	224
6	Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study International Journal of Gynecological Cancer ·Dana M. Chase, Helen Huang, Bradley J. Monk, Lois M. Ramondetta, Richard T. Penson, Karen M. Gil, Lisa M. Landrum, Mario M. Leitão, Ana Oaknin, Warner K. Huh, Heather Pulaski, Katina Robison, Saketh R. Guntupalli, Debra L. Richardson, Ritu Salani, Michael W. Sill, Lari Wenzel, Krishnansu S. Tewari	2020	5
7	Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study Gynecologic Oncology ·David E. Cohn, Michael W. Sill, Joan L. Walker, David M. O’Malley, Christa Nagel, Teresa Rutledge, William H. Bradley, Debra L. Richardson, Katherine Moxley, Carol Aghajanian	2017	61
8	Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study Journal of Clinical Oncology ·Bradley J. Monk, Michael W. Sill, Joan L. Walker, Christopher J. Darus, Gregory P. Sutton, Krishnansu S. Tewari, Lainie P. Martin, Jeanne M. Schilder, Robert L. Coleman, Jai Balkissoon, Carol Aghajanian	2016	60
9	A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D Gynecologic Oncology ·David M. Hyman, Michael W. Sill, Heather A. Lankes, Richard Piekarz, Mark S. Shahin, Mildred Ridgway, Floor Backes, Meaghen E Tenney, Cara Mathews, James Hoffman, Carol Aghajanian, Martee L. Hensley	2016	18
10	Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study Clinical Cancer Research ·Krishnansu S. Tewari, Michael W. Sill, Bradley J. Monk, Richard T. Penson, Harry J. Long, Andrés Poveda, Lisa M. Landrum, Mario M. Leitão, Jubilee Brown, Thomas Reid, Helen E. Michael, David H. Moore	2015	53
11	Improved Survival with Bevacizumab in Advanced Cervical Cancer New England Journal of Medicine ·Krishnansu S. Tewari, Michael W. Sill, Harry J. Long, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão, Helen E. Michael, Bradley J. Monk Hit paper breakdown →	2014	1025
12	A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study Gynecologic Oncology ·Kimberly K. Leslie, Michael W. Sill, Edgar Fischer, Kathleen M. Darcy, Robert S. Mannel, Krishnansu S. Tewari, Parviz Hanjani, Jason A. Wilken, Andre T. Baron, Andrew K. Godwin, Russell J. Schilder, Meenakshi Singh, Nita J. Maihle	2013	46
13	A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: A Gynecologic Oncology Group study Gynecologic Oncology ·D. Scott McMeekin, Michael W. Sill, Kathleen M. Darcy, Ovadia Abulafia, Parviz Hanjani, Michael L. Pearl, Stephen C. Rubin, Peter G. Rose, Laurie Small, Doris M. Benbrook	2012	13
14	Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study Journal of Clinical Oncology ·Carol Aghajanian, Michael W. Sill, Kathleen M. Darcy, Benjamin E. Greer, D. Scott McMeekin, Peter G. Rose, Jacob Rotmensch, Mack N. Barnes, Parviz Hanjani, Kimberly K. Leslie	2011	214
15	Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study Gynecologic Oncology ·Alessandro D. Santin, Michael W. Sill, D. Scott McMeekin, Mario M. Leitão, Jubilee Brown, Gregory P. Sutton, Linda Van Le, Patricia Griffin, Cecelia H. Boardman	2011	82
16	A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: A gynecologic oncology group study Gynecologic Oncology ·Peter G. Rose, Michael W. Sill, D. Scott McMeekin, Amina Ahmed, Ritu Salani, S. Diane Yamada, Aaron H. Wolfson, Nancy Fusco, Paula M. Fracasso	2011	14
17	Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group Gynecologic Oncology ·Charles A. Kunos, Michael W. Sill, Thomas Buekers, Joan L. Walker, Jeanne M. Schilder, S. Diane Yamada, Steven Waggoner, Mohammed Mohiuddin, Paula M. Fracasso	2010	41
18	Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study Gynecologic Oncology ·Gini F. Fleming, Michael W. Sill, Kathleen M. Darcy, D. Scott McMeekin, J.T. Thigpen, Lisa Adler, Jonathan S. Berek, Julia Chapman, Paul DiSilvestro, Ira Horowitz, James V. Fiorica	2009	200
19	Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study Gynecologic Oncology ·Martee L. Hensley, Michael W. Sill, Dennis R. Scribner, Jubilee Brown, Robert Debernardo, Ellen M. Hartenbach, Carolyn K. McCourt, James Bosscher, Paola A. Gehrig	2009	71
20	Drop-the-losers design: Binomial case Computational Statistics & Data Analysis ·Michael W. Sill, Allan R. Sampson	2008	23

About Michael W. Sill

Michael W. Sill is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Pulmonary and Respiratory Medicine, Oncology and Surgery, having authored 110 papers that have together received 6.2k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (69 papers), Endometrial and Cervical Cancer Treatments (47 papers), Intraperitoneal and Appendiceal Malignancies (22 papers), Angiogenesis and VEGF in Cancer (14 papers), Renal cell carcinoma treatment (11 papers), Lung Cancer Treatments and Mutations (9 papers), Sarcoma Diagnosis and Treatment (8 papers) and Endometriosis Research and Treatment (8 papers). The work is most often cited by research in Reproductive Medicine (2.6k citations), Obstetrics and Gynecology (2.4k citations), Oncology (2.4k citations), Pathology and Forensic Medicine (976 citations) and Cancer Research (631 citations). Michael W. Sill has collaborated with scholars based in United States, Spain and Palestinian Territory. Frequent co-authors include Bradley J. Monk, Robert A. Burger, Lois M. Ramondetta, Benjamin E. Greer, D. Scott McMeekin, Krishnansu S. Tewari, Joel I. Sorosky, Kathleen M. Darcy, Mario M. Leitão and Lisa M. Landrum. Their work appears in journals such as Gynecologic Oncology, Journal of Clinical Oncology, International Journal of Gynecological Cancer, Journal of Midwifery & Women s Health and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact